{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:59:15Z","timestamp":1778608755452,"version":"3.51.4"},"reference-count":66,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nabriva Therapeutics GmbH, Vienna Austria","award":["882391"],"award-info":[{"award-number":["882391"]}]},{"DOI":"10.13039\/501100004955","name":"Austrian Research Promotion Agency (FFG)","doi-asserted-by":"publisher","award":["882391"],"award-info":[{"award-number":["882391"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lefamulin is a first-in-class systemic pleuromutilin antimicrobial and potent inhibitor of bacterial translation, and the most recent novel antimicrobial approved for the treatment of community-acquired pneumonia (CAP). It exhibits potent antibacterial activity against the most prevalent bacterial pathogens that cause typical and atypical pneumonia and other infectious diseases. Early studies indicate additional anti-inflammatory activity. In this study, we further investigated the immune-modulatory activity of lefamulin in the influenza A\/H1N1 acute respiratory distress syndrome (ARDS) model in BALB\/c mice. Comparators included azithromycin, an anti-inflammatory antimicrobial, and the antiviral oseltamivir. Lefamulin significantly decreased the total immune cell infiltration, specifically the neutrophils, inflammatory monocytes, CD4+ and CD8+ T-cells, NK cells, and B-cells into the lung by Day 6 at both doses tested compared to the untreated vehicle control group (placebo), whereas azithromycin and oseltamivir did not significantly affect the total immune cell counts at the tested dosing regimens. Bronchioalveolar lavage fluid concentrations of pro-inflammatory cytokines and chemokines including TNF-\u03b1, IL-6, IL-12p70, IL-17A, IFN-\u03b3, and GM-CSF were significantly reduced, and MCP-1 concentrations were lowered (not significantly) by lefamulin at the clinically relevant \u2018low\u2019 dose on Day 3 when the viral load peaked. Similar effects were also observed for oseltamivir and azithromycin. Lefamulin also decreased the viral load (TCID50) by half a log10 by Day 6 and showed positive effects on the gross lung pathology and survival. Oseltamivir and lefamulin were efficacious in the suppression of the development of influenza-induced bronchi-interstitial pneumonia, whereas azithromycin did not show reduced pathology at the tested treatment regimen. The observed anti-inflammatory and immune-modulatory activity of lefamulin at the tested treatment regimens highlights a promising secondary pharmacological property of lefamulin. While these results require confirmation in a clinical trial, they indicate that lefamulin may provide an immune-modulatory activity beyond its proven potent antibacterial activity. This additional activity may benefit CAP patients and potentially prevent acute lung injury (ALI) and ARDS.<\/jats:p>","DOI":"10.3390\/ijms25105401","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T11:31:52Z","timestamp":1715772712000},"page":"5401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5594-1621","authenticated-orcid":false,"given":"Susanne","family":"Paukner","sequence":"first","affiliation":[{"name":"Nabriva Therapeutics GmbH, Leberstrasse 20, 1110 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kimber","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Cumper","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Rea-Davies","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Sueiro Ballesteros","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kirkham","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"PathCelerate Ltd., Cheshire CW4 8PW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Gelone","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., Fort Washington, PA 19034, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Richards","sequence":"additional","affiliation":[{"name":"Charles River Discovery, Portishead BS20 7AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang W.","family":"Wicha","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics GmbH, Leberstrasse 20, 1110 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3389\/fimmu.2020.01722","article-title":"Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury","volume":"11","author":"Kumar","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1590\/1414-431x20144402","article-title":"IL-6 and TNF-\u03b1 serum levels are associated with early death in community-acquired pneumonia patients","volume":"48","author":"Bacci","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gu, Y., Zuo, X., Zhang, S., Ouyang, Z., Jiang, S., Wang, F., and Wang, G. (2021). The Mechanism behind Influenza Virus Cytokine Storm. Viruses, 13.","DOI":"10.3390\/v13071362"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"Osuchowski","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1473-3099(13)70286-X","article-title":"Pathogenesis of influenza-induced acute respiratory distress syndrome","volume":"14","author":"Short","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1172\/JCI60331","article-title":"The acute respiratory distress syndrome","volume":"122","author":"Matthay","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(67)90168-7","article-title":"Acute respiratory distress in adults","volume":"2","author":"Ashbaugh","year":"1967","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"Pickkers","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"921452","DOI":"10.3389\/fmed.2022.921452","article-title":"Immunomodulatory therapies for COVID-19","volume":"9","author":"Mathur","year":"2022","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210093","DOI":"10.1183\/16000617.0093-2021","article-title":"Antibiotics as immunomodulators: A potential pharmacologic approach for ARDS treatment","volume":"30","author":"Sauer","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections","volume":"2023","author":"Tamma","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","first-page":"1","article-title":"Use of immunomodulatory therapy as part of comprehensive treatment of non-severe community-acquired pneumonia and its long-term results","volume":"12","author":"Kostinov","year":"2023","journal-title":"Drugs Context"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/arh.2017.08.01","article-title":"Current and emerging evidence for immunomodulatory therapy in community-acquired pneumonia","volume":"1","author":"Woods","year":"2017","journal-title":"Ann. Res. Hosp."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kournoutou, G.G., and Dinos, G. (2022). Azithromycin through the Lens of the COVID-19 Treatment. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081063"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155263","DOI":"10.1016\/j.cyto.2020.155263","article-title":"Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia\u2014Unravelling potential causal relationships","volume":"136","author":"Rosolowski","year":"2020","journal-title":"Cytokine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","article-title":"Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study","volume":"167","author":"Kellum","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1183\/09031936.00040710","article-title":"Factors associated with inflammatory cytokine patterns in community-acquired pneumonia","volume":"37","author":"Martinez","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/thoraxjnl-2013-204742","article-title":"Pulmonary retention of primed neutrophils: A novel protective host response, which is impaired in the acute respiratory distress syndrome","volume":"69","author":"Summers","year":"2014","journal-title":"Thorax"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kwon, J.W., Quan, H., Song, J., Chung, H., Jung, D., Hong, J.J., Na, Y.R., and Seok, S.H. (2022). Liposomal Dexamethasone Reduces A\/H1N1 Influenza-Associated Morbidity in Mice. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.845795"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1183\/09031936.00074410","article-title":"Systemic cytokine response in patients with community-acquired pneumonia","volume":"37","author":"Endeman","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mayocp.2014.09.006","article-title":"Non-anti-infective effects of antimicrobials and their clinical applications: A review","volume":"90","author":"Sadarangani","year":"2015","journal-title":"Mayo. Clin. Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.201903-0706ED","article-title":"Azithromycin: The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?","volume":"200","author":"Welte","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The Immunomodulatory Effects of Macrolides\u2014A Systematic Review of the Underlying Mechanisms","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_27","unstructured":"European Medicines Agency (EMA) (2024, May 12). Xenleta, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xenleta."},{"key":"ref_28","unstructured":"Food and Drug Administration (FDA) (2024, May 12). XENLETA (Lefamulin) Injection, for Intravenous Use; XENLETA (Lefamulin) Tablets, for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211672s000,211673s000lbl.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s40495-022-00297-6","article-title":"Lefamulin: A New Hope in the Field of Community-Acquired Bacterial Pneumonia","volume":"8","author":"Adhikary","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40121-020-00378-3","article-title":"Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin","volume":"10","author":"Eraikhuemen","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jgar.2021.10.021","article-title":"Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin","volume":"29","author":"Paukner","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Paukner, S., Mariano, D., Das, A.F., Moran, G.J., Sandrock, C., Waites, K.B., and File, T.M. (2021). Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121489"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dkad389","article-title":"7-Year (2015\u201321) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms","volume":"79","author":"Paukner","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40265-020-01443-4","article-title":"Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia","volume":"81","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/joim.13378","article-title":"Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic","volume":"291","author":"Covvey","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.02106-12","article-title":"Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections","volume":"57","author":"Prince","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e02380-17","DOI":"10.1128\/AAC.02380-17","article-title":"In vitro activity of lefamulin against sexually transmitted bacterial pathogens","volume":"62","author":"Paukner","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10753-010-9186-3","article-title":"Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice","volume":"33","author":"Chen","year":"2010","journal-title":"Inflammation"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hafner, M., Paukner, S., Wicha, W.W., Hrva\u010di\u0107, B., Cedilak, M., Faraho, I., and Gelone, S.P. (2021). Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0237659"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.intimp.2009.02.018","article-title":"Valnemulin downregulates nitric oxide, prostaglandin E2, and cytokine production via inhibition of NF-kappaB and MAPK activity","volume":"9","author":"Zhang","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(00)74657-5","article-title":"The susceptibility of mice to the viruses of human and swine influenza","volume":"224","author":"Andrewes","year":"1934","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zak, O.S., and Sande, M.A. (1999). Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy, Academic Press. Chapter 118.","DOI":"10.1097\/00024382-200003000-00016"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jia, X., Liu, B., Bao, L., Lv, Q., Li, F., Li, H., An, Y., Zhang, X., Cao, B., and Wang, C. (2018). Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007428"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fukushi, M., Ito, T., Oka, T., Kitazawa, T., Miyoshi-Akiyama, T., Kirikae, T., Yamashita, M., and Kudo, K. (2011). Serial Histopathological examination of the lungs of mice infected with influenza a virus PR8 strain. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021207"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajpath.2011.03.013","article-title":"Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis","volume":"179","author":"Narasaraju","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E6622","DOI":"10.1073\/pnas.1806265115","article-title":"In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs","volume":"115","author":"Ueki","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"A110","DOI":"10.1016\/j.antiviral.2008.12.014","article-title":"Animal models for the study of influenza pathogenesis and therapy","volume":"82","author":"Barnard","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/095632020601700403","article-title":"Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza a (H1N1) and B viruses","volume":"17","author":"Smee","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Sun, H., Fan, L., Ma, Y., Sun, Y., Pu, J., Yang, J., Qiao, J., Ma, G., and Liu, J. (2012). Acute respiratory distress syndrome induced by a swine 2009 H1N1 variant in mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029347"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"III11","DOI":"10.1093\/jac\/dkz086","article-title":"Pharmacokinetics\/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae","volume":"74","author":"Wicha","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1128\/AAC.35.6.1024","article-title":"Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia","volume":"35","author":"Bedos","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","unstructured":"(2024, May 12). Food and Drug Administration (FDA) ZITHROMAX (Azithromycin Tablets and Azithromycin for Oral Suspension), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050710s039,050711s036,050784s023lbl.pdf."},{"key":"ref_53","first-page":"505","article-title":"Clinical pharmacokinetics of azithromycin","volume":"43","author":"Singlas","year":"1995","journal-title":"Pathol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"L231","DOI":"10.1152\/ajplung.00049.2003","article-title":"Evaluation of lung injury in rats and mice","volume":"286","author":"Parker","year":"2004","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process","volume":"72","author":"Tran","year":"2019","journal-title":"J. Antibiot."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4049\/jimmunol.1701406","article-title":"Effects of Influenza on Alveolar Macrophage Viability Are Dependent on Mouse Genetic Strain","volume":"201","author":"Califano","year":"2018","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00103-20","DOI":"10.1128\/CMR.00103-20","article-title":"Viral Respiratory Pathogens and Lung Injury","volume":"34","author":"Clementi","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jmv.24911","article-title":"The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus","volume":"89","author":"Fage","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"735443","DOI":"10.3389\/fphar.2021.735443","article-title":"GM-CSF: Orchestrating the Pulmonary Response to Infection","volume":"12","author":"McCormick","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","article-title":"GM-CSF-based treatments in COVID-19: Reconciling opposing therapeutic approaches","volume":"20","author":"Lang","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/SHK.0000000000000123","article-title":"Interleukin 10 overexpression alters survival in the setting of gram-negative pneumonia following lung contusion","volume":"41","author":"Dolgachev","year":"2014","journal-title":"Shock"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41598-017-01225-1","article-title":"Early measurement of IL-10 predicts the outcomes of patients with acute respiratory distress syndrome receiving extracorporeal membrane oxygenation","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1183\/09031936.02.00295102","article-title":"Systemic cytokine levels in community-acquired pneumonia and their association with disease severity","volume":"20","author":"Antunes","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4049\/jimmunol.2100328","article-title":"IFN-gamma Drives TNF-alpha Hyperproduction and Lethal Lung Inflammation during Antibiotic Treatment of Postinfluenza Staphylococcus aureus Pneumonia","volume":"207","author":"Verma","year":"2021","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:53Z","timestamp":1760107373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":66,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25105401"],"URL":"https:\/\/doi.org\/10.3390\/ijms25105401","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}